Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Hall

Showing results (191-200 of 226) with videos related to

Pageof 23
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 10, 2024
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trialPasquale Rescigno, Nuria Porta, Laura Finneran, et al.
International Journal of Radiation Oncology, Biology, Physics|March 20, 2019
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder CancerAlexandra K Walker, Katalin Karaszi, Helen Valentine, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
The Lancet. Oncology|June 25, 2016
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trialDavid Dearnaley, Isabel Syndikus, Helen Mossop, et al.
Cancer Discovery|May 28, 2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSuzanne Carreira, Nuria Porta, Sara Arce-Gallego, et al.
The Lancet. Oncology|October 31, 2020
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion studyChristina Guo, Maxime Chénard-Poirier, Desamparados Roda, et al.
Health Technology Assessment (Winchester, England)|October 27, 2022
Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCTRakesh Heer, Rebecca Lewis, Anne Duncan, et al.
BJC Reports|November 8, 2024
Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genesSarah Benafif, Ann-Britt Jones, Susan Merson, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2021
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trialChristopher M Nutting, Clare L Griffin, Paul Sanghera, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2018
Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004)Christopher M Nutting, James P Morden, Matthew Beasley, et al.
Pageof 23

Showing results (191-200 of 226) with videos related to

Sort By:
Pageof 23
European Journal of Cancer (Oxford, England : 1990)|May 10, 2024
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trialPasquale Rescigno, Nuria Porta, Laura Finneran, et al.
International Journal of Radiation Oncology, Biology, Physics|March 20, 2019
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder CancerAlexandra K Walker, Katalin Karaszi, Helen Valentine, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
The Lancet. Oncology|June 25, 2016
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trialDavid Dearnaley, Isabel Syndikus, Helen Mossop, et al.
Cancer Discovery|May 28, 2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSuzanne Carreira, Nuria Porta, Sara Arce-Gallego, et al.
The Lancet. Oncology|October 31, 2020
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion studyChristina Guo, Maxime Chénard-Poirier, Desamparados Roda, et al.
Health Technology Assessment (Winchester, England)|October 27, 2022
Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCTRakesh Heer, Rebecca Lewis, Anne Duncan, et al.
BJC Reports|November 8, 2024
Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genesSarah Benafif, Ann-Britt Jones, Susan Merson, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2021
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trialChristopher M Nutting, Clare L Griffin, Paul Sanghera, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2018
Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004)Christopher M Nutting, James P Morden, Matthew Beasley, et al.
Pageof 23